Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Instil Bio(US:TIL) Seeking Alphaยท2025-05-25 11:09Company Overview - Instil Bio (TIL) and its partner ImmuneOnco are advancing their bispecific antibody AXN-2510, targeting PD-1/VEGF for solid tumors treatment [2] Investment Analysis - The Biotech Analysis Central service offers extensive resources for investors, including over 600 articles and a model portfolio of small and mid-cap stocks [2]